Evotec, Roche Ink Drug Discovery Deal

Evotec OAI has entered into a "worldwide discovery chemistry agreement" with Roche, the companies announced on May 12.

This is the fourth chemistry alliance between the two companies since the first one was struck in 2001, when Evotec began supporting Roche at four sites in the design and synthesis of chemical compounds, which Roche added to its compound library for drug screening, the companies said.

In 2003, the companies said they expanded the partnership to encompass medicinal chemistry.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A phylogenetic analysis indicates two venomous Australian spiders are more closely related than thought, the International Business Times reports.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.

In Science this week: CRISPR-based approach for recording cellular events, and more.

A new company says it will analyze customers' genes to find them a suitable date, though Smithsonian magazine says the science behind it might be shaky.